Marcelo Cypel, M.D., Jonathan C. Yeung, M.D., Mingyao Liu, M.D., Masaki Anraku, M.D., Fengshi Chen, M.D., Ph.D., Wojtek Karolak, M.D., Masaaki Sato, M.D., Ph.D., Jane Laratta, R.N., Sassan Azad, C.R.A., Mindy Madonik, C.C.P., Chung-Wai Chow, M.D., Cecilia Chaparro, M.D., Michael Hutcheon, M.D., Lianne G. Singer, M.D., Arthur S. Slutsky, M.D., Kazuhiro Yasufuku, M.D., Ph.D., Marc de Perrot, M.D., Andrew F. Pierre, M.D., Thomas K. Waddell, M.D., Ph.D., and Shaf Keshavjee, M.D.: Normothermic Ex Vivo Lung Perfusion in Clinical Lung Transplantation.Individuals were ineligible if a contraindication was had by them to continued anticoagulant therapy or if indeed they required ongoing anticoagulant therapy, dual antiplatelet therapy, or aspirin in a dose greater than 165 mg daily. Extra ineligibility requirements included a hemoglobin level of less than 9 mg per deciliter, a platelet count of less than 100,000 per cubic millimeter, a serum creatinine degree of a lot more than 2.5 times the upper limit of the normal range. The full list of exclusion criteria is provided in the process. Randomization Randomization was performed by using an interactive voice-response system and was stratified based on the initial analysis and participation or zero participation in the AMPLIFY trial.